CognitiveResearch Phase

Orexin B

Intracerebroventricular

Overview

Orexin B is a 28-amino acid neuropeptide closely related to orexin A, also synthesized in hypothalamic neurons and involved in promoting wakefulness and regulating feeding behavior. It exhibits preferential binding to orexin receptor 2 (OX2R) compared to OX1R.

Mechanism of Action

Orexin B contributes to the maintenance of arousal and the integration of metabolic and circadian signals..

Research Summary & Key Findings

Animal studies have shown that orexin B administration promotes wakefulness and reduces sleep latency, with effects generally considered less potent than orexin A in arousal models. Published data in sleep research and endocrinology journals support its role in vigilance state control. As with orexin A, poor pharmacokinetic properties and blood-brain barrier limitations have precluded clinical development of the native peptide.

Clinical Status

Research Phase

Orexin B is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Intracerebroventricular

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers Orexin B therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Orexin B.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.